NeoCOAST-2 Data Shows Combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data Builds on AEGEAN Study Research

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens. SAN DIEGO, Sept. 8, 2024 /PRNewswire-PRWeb/ -- NeoCOAST-2 Data Shows Combination of Durvalumab with...